Drugs for Diastolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 133)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Atorvastatin |
Approved |
Phase 4 |
|
134523-00-5 |
60823 |
|
Synonyms:
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
134523-00-5
134523-03-8
7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
AC-15611
AC1L1TZT
AC1Q1OZQ
AKOS000281127
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
atorvastatin
Atorvastatin
Atorvastatin (INN)
Atorvastatin [INN:BAN]
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
atorvastatina
Atorvastatina
atorvastatine
Atorvastatine
atorvastatinium
atorvastatinum
Atorvastatinum
atrovastin
BIDD:GT0336
C06834
C33H35FN2O5
|
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
Cardyl
CCRIS 7159
CHEBI:39548
CHEMBL1487
CI 981
CID60823
D07474
DB01076
Faboxim
Hipolixan
HSDB 7039
Hydrate, atorvastatin calcium
Lipitor
Lipitor (TN)
Lipitor(TM)
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
LS-136975
MolPort-000-883-773
NCGC00159458-02
nchembio.301-comp8
Normalip
Sincol
Sortis
Sortis (TN)
Sotis
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
UNII-A0JWA85V8F
Vastina
Xanator
Xarator
Xavator
Zurinel
|
|
| 2 |
|
Adalimumab |
Approved |
Phase 4 |
|
331731-18-1 |
16219006 |
|
Synonyms:
331731-18-1
Adalimumab
Adalimumab (genetical recombination)
Adalimumab (genetical recombination) (JAN)
Adalimumab (USAN/INN)
adalimumab-adaz
adalimumab-adbm
adalimumab-afzb
|
adalimumab-atto
adalimumab-bwwd
D02597
Humira
Humira (TN)
Humira Pen
Ig gamma-1 chain C region
|
|
| 3 |
|
Infliximab |
Approved |
Phase 4 |
|
170277-31-3 |
|
|
Synonyms:
Ig gamma-1 chain C region
Infliximab (genetical recombination)
Infliximab-abda
Infliximab-axxq
|
Infliximab-dyyb
Infliximab-qbtx
Remicade
|
|
| 4 |
|
Etanercept |
Approved, Investigational |
Phase 4 |
|
185243-69-0 |
|
|
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
etanercept
Etanercept
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
Etanercept (USAN/INN)
etanercept-szzs
|
etanercept-ykro
p75
p80 TNF-alpha receptor
Recombinant human TNF
rhu TNFR:Fc
rhu-TNFR:Fc
TNF-R2
TNFR-Immunoadhesin
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
|
|
| 5 |
|
Valsartan |
Approved, Investigational |
Phase 4 |
|
137862-53-4 |
60846 |
|
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
|Tareg
137862-53-4
AC1L1U1M
AC1Q5QIK
AC-4543
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
Bio-0796
BRD-K45158365-001-02-3
BSPBio_003501
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
Kalpress
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
Lacer brand of valsartan
|
LS-161334
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
Miten
MLS000759423
MLS001424088
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Nisis
Nisis||
Novartis brand of valsartan
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Provas
S1894_Selleck
SAM001246581
Sanol brand of valsartan
Schwarz brand of valsartan
SMR000466318
SPBio_001260
Spectrum_001796
SPECTRUM1505209
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Tareg
TL8000869
UNII-80M03YXJ7I
Vals
Valsarran
valsartan
Valsartan
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
walsartan
|
|
| 6 |
|
Angiotensin II |
Approved, Investigational |
Phase 4 |
|
4474-91-3, 11128-99-7, 68521-88-0 |
172198 |
|
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-isoleucine-angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-isoleucineangiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
|
Angiotensin-(1-8) octapeptide
Angiotonin
Asp-arg-val-tyr-ile-his-pro-phe
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
| 7 |
|
Dopamine |
Approved |
Phase 4 |
|
51-61-6, 62-31-7 |
681 |
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
| 8 |
|
Sodium citrate |
Approved, Investigational |
Phase 4 |
|
68-04-2 |
|
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
| 9 |
|
Allopurinol |
Approved |
Phase 4 |
|
315-30-0 |
2094 |
|
Synonyms:
1,5-dihydro-4H-pyrazolo(3,4-D)Pyrimidin-4-one
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one
1,5-dihydro-4H-pyrazolo(3,4-D)Pyrimidine-4-one
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
184856-42-6
1H-pyrazolo(3,4-D)Pyrimidin-4-ol
1H-Pyrazolo(3,4-d)pyrimidin-4-ol
22767-92-6
315-30-0
39464-14-7
4-HPP
4H-pyrazolo(3,4-D)Pyrimidin-4-one
4H-Pyrazolo(3,4-d)pyrimidin-4-one
4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine
4-Hydroxy-1H-pyrazolo(3,4-D)pyrimidine
4-Hydroxy-3,4-pyrazolopyrimidine
4-hydroxypyrazolo(3,4-D)Pyrimidine
4-Hydroxypyrazolo(3,4-d)pyrimidine
4'-Hydroxypyrazolol(3,4-d)pyrimidine
4'-Hydroxypyrazolol(3,4-D)pyrimidine
4-Hydroxypyrazolopyrimidine
4-Hydroxypyrazolyl(3,4-d)pyrimidine
4-Hydroxypyrazolyl(3,4-D)pyrimidine
7HP
A 8003
A0907
A8003_SIGMA
AC-019
AC1L1CWL
AC1Q6FWV
AC1Q6GP7
Adenock
Ailural
Ailurial
AKOS000267490
AKOS000269759
AL-100
Allohexal
Allohexan
Alloprin
Allopur
Allo-Puren
Allopurin
allopurinol
Allopurinol
Allopurinol alphapharm brand
Allopurinol amrad brand
Allopurinol aps brand
Allopurinol ashbourne brand
Allopurinol azupharma brand
Allopurinol basf brand
Allopurinol bicther brand
Allopurinol boots brand
Allopurinol clonmel brand
Allopurinol dorsch brand
Allopurinol douglas brand
Allopurinol gepepharm brand
Allopurinol hennig brand
Allopurinol hexal brand
Allopurinol horner brand
Allopurinol icn brand
Allopurinol jenapharm brand
Allopurinol merckle brand
Allopurinol merz brand
Allopurinol multipharma brand
Allopurinol nicholas brand
Allopurinol novopharm brand
Allopurinol pharmafarm brand
Allopurinol pinewood brand
Allopurinol protea brand
Allopurinol r.a.n. brand
Allopurinol rima brand
Allopurinol roche brand
Allopurinol rosen brand
Allopurinol rougier brand
Allopurinol Sodium
Allopurinol tad brand
Allopurinol thiemann brand
Allopurinol wellcome brand
Allopurinol(I)
Allopurinolum
Allopurinolum [INN-Latin]
Allorin
Allozym
Allpargin
Allural
Aloprim
Alopurinol
Alopurinol [INN-Spanish]
Aloral
Alositol
Alphapharm brand OF allopurinol
Aluline
Amrad brand OF allopurinol
Anoprolin
Anzief
Apo-Allopurinol
APS brand OF allopurinol
Apulonga
Apurin
Apurol
Ashbourne brand OF allopurinol
Atisuril
Azupharma brand OF allopurinol
B. W. 56-158
BASF brand OF allopurinol
BB_SC-5394
Bicther brand OF allopurinol
BIM-0061756.0001
Bio-0799
Bleminol
Bloxanth
Boehringer mannheim brand OF allopurinol
Boots brand OF allopurinol
BSPBio_001798
BW 56158
BW 56-158
BW-56-158
Byk gulden brand OF allopurinol
C5H4N4O
Caplenal
Capurate
CCRIS 626
Cellidrin
CHEBI:40279
CHEBI:495607
CHEMBL1467
CID2094
Clonmel brand OF allopurinol
Cosuric
CPD000059083
CPD-9024
D000493
Dabrosin
Dabroson
DB00437
DivK1c_000685
Dorsch brand OF allopurinol
Douglas brand OF allopurinol
Dura Al
EINECS 206-250-9
|
Embarin
EN000932
Epidropal
Epuric
EU-0100102
Fawns and mcallan brand OF allopurinol
Foligan
Geapur
Gepepharm brand OF allopurinol
Gichtex
glaxo Wellcome brand OF allopurinol
Gotax
Hamarin
Hennig brand OF allopurinol
Henning berlin brand OF allopurinol
Hexal brand OF allopurinol
Hexanuret
HMS1920A15
HMS2091G15
HMS502C07
Horner brand OF allopurinol
HPP
HSDB 3004
I03-0052
ICN brand OF allopurinol
IDI1_000685
Jenapharm brand OF allopurinol
Jenapurinol
Jsp005881
KBio1_000685
KBio2_000386
KBio2_002954
KBio2_005522
KBio3_001298
KBioGR_000550
KBioSS_000386
Ketanrift
Ketobun-A
Ledopur
Lopac0_000102
Lopac-A-8003
Lopurin
LS-1180
Lysuron
Merckle brand OF allopurinol
Merz brand OF allopurinol
Milurit
Milurite
Miniplanor
MLS000069453
MLS001148183
MolPort-000-141-383
MolPort-000-870-337
MolPort-004-758-159
MolPort-004-758-166
MolPort-004-758-167
MolPort-004-758-643
Monarch
Multipharma brand OF allopurinol
NCGC00015094-01
NCGC00015094-03
NCGC00015094-06
NCGC00091134-01
NCGC00091134-02
NCGC00091134-03
NCGC00094580-01
NCGC00094580-02
nchembio.92-comp3
nchembio732-comp4
NCIOpen2_001825
Nektrohan
Nicholas brand OF allopurinol
NINDS_000685
Novopharm brand OF allopurinol
Novopurol
NSC 101655
NSC 1390
NSC101655
NSC1390
NSC-1390
Pan quimica
Pan Quimica
Pharmafarm brand OF allopurinol
Pinewood brand OF allopurinol
Prestwick_511
Progout
Protea brand OF allopurinol
Pureduct
Purinol
Quimica, pan
Quimica, Pan
R.A.N. brand OF allopurinol
Reig jofre brand OF allopurinol
Remid
Rhône poulenc rorer brand OF allopurinol
Rhône-poulenc rorer brand OF allopurinol
Riball
Rima brand OF allopurinol
Rimapurinol
Roche brand OF allopurinol
Rosen brand OF allopurinol
Roucol
Rougier brand OF allopurinol
S1630_Selleck
SAM002554884
Sigapurol
SMR000059083
SPBio_000056
Spectrum_000026
SPECTRUM1500108
Spectrum2_000098
Spectrum3_000289
Spectrum4_000135
Spectrum5_000768
STK378584
STK711106
Suspendol
TAD brand OF allopurinol
Takanarumin
Thiemann brand OF allopurinol
Tipuric
UNII-63CZ7GJN5I
Urbol
Uribenz
Uricemil
Uridocid
Uriprim
Uripurinol
Uritas
Urobenyl
Urolit
Urosin
Urtias
Urtias 100
Wellcome brand OF allopurinol
Xanthomax
Xanturat
Xanturic
Zygout
Zyloprim
Zyloric
|
|
| 10 |
|
Adenosine |
Approved, Investigational |
Phase 4 |
|
58-61-7 |
60961 |
|
Synonyms:
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-amino-9H-Purin-9-yl)-1-deoxy-beta-delta-ribofuranose
1-(6-amino-9H-Purin-9-yl)-1-deoxy-beta-D-ribofuranose
1odi
2fqy
2gl0
30143-02-3
46946-45-6
46969-16-8
4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside
58-61-7
6-Amino-9-.beta.-ribofuranosyl-9H-purine
6-amino-9-b-D-Ribofuranosyl-9H-purine
6-amino-9beta-delta-Ribofuranosyl-9H-purine
6-amino-9beta-D-Ribofuranosyl-9H-purine
6-amino-9-beta-D-Ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-amino-9-β-D-ribofuranosyl-9H-purine
9-(beta-D-Arabinofuranosyl)adenine
9-b-D-Ribofuranosidoadenine
9-b-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9beta-delta-Ribofuranosyladenine
9-beta-delta-Ribofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9beta-D-Ribofuranosyladenine
9-beta-D-Ribofuranosyladenine
9-β-D-ribofuranosidoadenine
9-β-D-ribofuranosyl-9H-purin-6-amine
A0152
A4036_SIGMA
A9251_SIGMA
AC1L1U8O
AC1Q1ID3
AC1Q52XU
Adenin riboside
Adenine 9-beta-D-arabinofuranoside
Adenine deoxyribonucleoside
Adenine Deoxyribonucleoside
Adenine nucleoside
Adenine riboside
Adenine-9beta-delta-ribofuranoside
Adenine-9beta-D-ribofuranoside
Adenine-9-beta-D-ribofuranoside
adenine-D-ribose
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenogesic
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosina
adenosine
Adenosine
Adénosine
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine, homopolymer
Adenosinum
Adensoine
Adenyldeoxyriboside
Ade-rib
Ade-Rib
|
ADN
Ado
AI3-52413
BB_NC-0565
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-delta-Adenosine
beta-D-Ribofuranoside, adenine-9
Bio1_000437
Bio1_000926
Bio1_001415
bmse000061
Boniton
BSPBio_001796
C00212
Caswell No. 010B
CCRIS 2557
CHEBI:16335
CHEMBL477
CID60961
D000241
D00045
DB00640
Deoxyadenosine
Desoxyadenosine
EA6C60C2-6AFB-4264-A2F0-541373DB950E
EINECS 200-389-9
FT-0082881
HMS1920A13
HMS2091G13
KBio3_001296
LS-15085
MEDR-640
MLS000069638
MLS002153227
MolPort-001-838-229
Myocol
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
nchembio.143-comp9
nchembio.186-comp109
nchembio.2007.56-comp13
nchembio.64-comp4
nchembio706-5
NSC 627048
NSC 7652
NSC627048
NSC7652
Nucleocardyl
Pallacor
Polyadenosine
Polyriboadenosine
S1647_Selleck
Sandesin
SDCCGMLS-0003108.P003
SMR000058216
SPBio_001194
SPECTRUM1500107
Spectrum2_001257
Spectrum3_000288
SR 96225
SR-96225
SUN-Y4001
TL8003749
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabine
ZINC02169830
β-D-adenosine
|
|
| 11 |
|
Regadenoson |
Approved, Investigational |
Phase 4 |
|
313348-27-5 |
219024 |
|
Synonyms:
|
| 12 |
|
Amlodipine |
Approved |
Phase 4 |
|
88150-42-9 |
2162 |
|
Synonyms:
()-Amlodipine
(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)
-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine
3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl ( -)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat
3-Ethyl-5-methyl ( -)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid
3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
88150-42-9
88150-47-4 (maleate (1:1))
AC1L1D26
AC1Q32ZS
AC-4535
Almirall brand OF amlodipine besilate
Ambap88150-42-9
Amlocard
amlodipine
Amlodipine
Amlodipine (INN)
Amlodipine [INN:BAN]
AMLODIPINE BASE
Amlodipine Benzenesulfonate
Amlodipine besilate
Amlodipine Besilate
Amlodipine besylate
Amlodipine Besylate
Amlodipine free base
Amlodipine Free Base
Amlodipine maleate
Amlodipine maleate (1:1)
Amlodipine, (+-)-isomer
Amlodipine, (+-)-isomer, maleate (1:1)
Amlodipine, (R)-isomer
Amlodipine, (S)-isomer, maleate (1:1)
Amlodipino
Amlodipino [Spanish]
Amlodipinum
Amlodipinum [Latin]
Amlodis
Amlopres
Amlor
|
Amvaz
AMVAZ
Astudal
BIDD:GT0810
BRD-A22032524-074-02-4
BRD-A22032524-074-03-2
BSPBio_002727
C06825
CHEBI:2668
CHEMBL1491
CID2162
Coroval
CPD000469198
D07450
DB00381
Eczacibasi brand OF amlodipine besilate
HMS2052N03
HMS2089H07
I14-0798
Intervask
Istin
KBio3_001947
KBioGR_001643
Lipinox
Lotrel
LS-131183
Mack brand OF amlodipine besilate
MLS001401409
MolPort-001-792-963
NCGC00165957-01
NCGC00165957-02
NCGC00165957-03
Norvasc
Norvasc (TN)
Pelmec
Pfizer brand OF amlodipine besilate
R,S)-Amlodipine
Racemic amlodipine
Racemic Amlodipine
SAM001246705
SMR000469198
SPBio_000351
Spectrum2_000486
Spectrum3_001004
Spectrum4_001132
Spectrum5_001550
UK-4834011
UNII-1J444QC288
|
|
| 13 |
|
Empagliflozin |
Approved |
Phase 4 |
|
864070-44-0 |
|
|
Synonyms:
(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
Empagliflozin
|
Empagliflozina
Empagliflozine
Empagliflozinum
|
|
| 14 |
|
Nebivolol |
Approved, Investigational |
Phase 4 |
|
99200-09-6, 118457-14-0, 152520-56-4 |
71301 |
|
Synonyms:
1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol
1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol
104365-59-5
118457-14-0
2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
99200-09-6
a,Alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
AC-1611
AC1L2FX8
AC1Q4OMF
alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol
alpha,Alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol
alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,Alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol)
Bystolic
C22H25F2NO4
CHEMBL434394
CID71301
D05127
DB04861
Hydrochloride, nebivolol
I06-0378
L001284
Lobivon
|
LS-178404
MolPort-003-849-343
Narbivolol
Nebicard-5
Nebilet
Nebilong
Nebipill
Nebivolol
Nebivolol (USAN/INN)
Nebivolol [USAN:INN:BAN]
Nebivolol hydrochloride
Nebivololum
nebivololum [latin]
Nebivololum [Latin]
Nodon
Nubeta
PDSP1_000244
PDSP2_000243
PI-21858
R 67555
R65,824
R-67555
Silostar
UNII-030Y90569U
α,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
|
|
| 15 |
|
Eplerenone |
Approved |
Phase 4 |
|
107724-20-9 |
150310 443872 |
|
Synonyms:
107724-20-9
7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
9,11-Epoxy-7-(methoxycarbonyl)-3-oxo-17-pregn-4-ene-21,17-carbolactone
AC1L9FDC
AC-4213
C12512
CGP-30083
CHEBI:31547
CHEBI:726453
CHEMBL1095097
CID443872
D01115
Eplerenon
Eplerenona
|
Eplerenone
Eplerenone (JAN/USAN/INN)
Epoxymexrenone
Inspra
Inspra (TN)
Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone
MolPort-003-986-216
NCGC00159559-01
NCGC00159559-02
S1707_Selleck
SC-66110
Selara
TL8000270
ZINC03985982
|
|
| 16 |
|
Exenatide |
Approved, Investigational |
Phase 4 |
|
141758-74-9 |
15991534 |
|
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
Byetta
C074031
CHEBI:490990
CHEMBL414357
Ex4 peptide
|
Exenatida
Exenatide
Exenatide synthetic
Exenatide Synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
|
|
| 17 |
|
Glucagon |
Approved |
Phase 4 |
|
16941-32-5 |
|
|
Synonyms:
Glucagon
Glucagon (recombinant dna origin)
Glucagon recombinant
Glucagon, human
|
Glucagon, porcine
Glucagone
Glucagonum
|
|
| 18 |
|
Ambrisentan |
Approved, Investigational |
Phase 4 |
|
177036-94-1 |
6918493 |
|
Synonyms:
(+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid
(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid
177036-94-1
2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid
2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
AC1L53VT
Ambrisentan
Ambrisentan [INN]
Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe
BSF 208075
BSF208075
BSF-208075
C467894
CHEBI:205299
CHEMBL302753
|
CID197712
Gilead brand of ambrisentan
I06-2077
Letairis
LS-186563
LS-187364
LU 208075
LU208075
LU-208075
MLS001195278
MolPort-002-945-567
NCGC00160662-01
SMR000502713
ST51051295
STK097095
UNII-HW6NV07QEC
|
|
| 19 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
77-92-9 |
311 |
|
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
| 20 |
|
Uric acid |
Investigational |
Phase 4 |
|
69-93-2 |
1175 |
|
Synonyms:
1H-Purine-2,6,8-triol
2,6,8-trihydroxypurine
2,6,8-Trihydroxypurine
2,6,8-trioxopurine
2,6,8-Trioxopurine
2,6,8-trioxypurine
2,6,8-Trioxypurine
7,9-dihydro-1H-purine-2,6,8(3H)-trione
Acid urate, ammonium
Acid urate, sodium
Acid, uric
Ammonium acid urate
Lithate
Lithic acid
Monohydrate, monosodium urate
Monohydrate, sodium urate
Monosodium urate
|
Monosodium urate monohydrate
Potassium urate
Purine-2,6,8(1H,3H,9H)-trione
Sodium acid urate
Sodium acid urate monohydrate
Sodium urate
Sodium urate monohydrate
Trioxopurine
Urate
Urate monohydrate, monosodium
Urate monohydrate, sodium
Urate, ammonium acid
Urate, monosodium
Urate, potassium
Urate, sodium
Urate, sodium acid
Uricum acidum
|
|
| 21 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
| 22 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4 |
|
|
|
| 23 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
| 24 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
| 25 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
| 26 |
|
Analgesics |
|
Phase 4 |
|
|
|
| 27 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
| 28 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
| 29 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
| 30 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
| 31 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
| 32 |
|
Hormones |
|
Phase 4 |
|
|
|
| 33 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
| 34 |
|
calcium channel blockers |
|
Phase 4 |
|
|
|
| 35 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 4 |
|
|
|
| 36 |
|
Angiotensinogen |
|
Phase 4 |
|
|
|
| 37 |
|
Angiotensin Receptor Antagonists |
|
Phase 4 |
|
|
|
| 38 |
|
Giapreza |
|
Phase 4 |
|
|
|
| 39 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
| 40 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
| 41 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
| 42 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
| 43 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
| 44 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 4 |
|
|
|
| 45 |
|
Citrate |
|
Phase 4 |
|
|
|
| 46 |
|
Sildenafil Citrate |
|
Phase 4 |
|
171599-83-0 |
|
| 47 |
|
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... |
|
Phase 4 |
|
|
|
| 48 |
|
LCZ 696 |
|
Phase 4 |
|
|
|
| 49 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
| 50 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 169)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker |
Unknown status |
NCT01072058 |
Phase 4 |
TNF blockers (infliximab, adalimumab, etanercept) |
| 2 |
Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) |
Unknown status |
NCT01503671 |
Phase 4 |
Atorvastatin |
| 3 |
A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure |
Completed |
NCT00171106 |
Phase 4 |
valsartan |
| 4 |
Novel Treatment for Diastolic Heart Failure in Women |
Completed |
NCT00206232 |
Phase 4 |
Spironolactone |
| 5 |
Randomized Evaluation of Heart Failure With Preserved Ejection Fraction (HFpEF) Patients With Acute Heart Failure and Dopamine (ROPA-DOP) Trial |
Completed |
NCT01901809 |
Phase 4 |
Furosemide;Dopamine |
| 6 |
Aldosterone Antagonism in Diastolic Heart Failure |
Completed |
NCT00108251 |
Phase 4 |
Eplerenone;Placebo |
| 7 |
Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart |
Completed |
NCT01944384 |
Phase 4 |
aldactone |
| 8 |
SIDAMI - Sildenafil and Diastolic Dysfunction After AMI |
Completed |
NCT01046838 |
Phase 4 |
Sildenafil;Placebo |
| 9 |
Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients |
Completed |
NCT00477789 |
Phase 4 |
allopurinol |
| 10 |
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF |
Completed |
NCT02589977 |
Phase 4 |
regadenoson |
| 11 |
Fimasartan for Improvement of Diastolic Dysfunction in Hypertensive Patients |
Completed |
NCT01691118 |
Phase 4 |
Fimasartan;Antihypertensive treatment |
| 12 |
Effect of Add-on of Amlodipine Versus Valsartan on Diastolic Dysfunction Associated With Hypertension |
Completed |
NCT02973035 |
Phase 4 |
Amlodipine;Valsartan |
| 13 |
DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? |
Completed |
NCT02956811 |
Phase 4 |
Dapagliflozin;Placebo |
| 14 |
A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus |
Recruiting |
NCT03753087 |
Phase 4 |
Empagliflozin |
| 15 |
A Proof of Concept Study to Determine the Efficacy of Entrestoâ„¢ in HFpEF Based on Circulating Neprilysin Levels: The Circulating NEP and NEP Inhibition (CNEPi) Study |
Recruiting |
NCT03506412 |
Phase 4 |
Entrestoâ„¢ 49Mg-51 mg tablet |
| 16 |
Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure |
Active, not recruiting |
NCT02053246 |
Phase 4 |
Nebivolol |
| 17 |
A Phase 4, Randomized, Open Label, Multicenter Prospective Comparative Study To Evaluate The Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure |
Not yet recruiting |
NCT04160000 |
Phase 4 |
Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation |
| 18 |
The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure |
Not yet recruiting |
NCT04071626 |
Phase 4 |
Ertugliflozin 5 mg;Placebo oral tablet |
| 19 |
Determine the Effectiveness of Eplerenone in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure ( PREDICT Study) |
Terminated |
NCT00293150 |
Phase 4 |
Eplerenone |
| 20 |
Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction |
Terminated |
NCT00799435 |
Phase 4 |
Exenatide |
| 21 |
The Use of Nesiritide in the Management of Acute Diastolic Heart Failure |
Terminated |
NCT00083772 |
Phase 4 |
Nesiritide |
| 22 |
Safety and Efficacy Trial Using Ambrisentan for Pulmonary Hypertension Associated With Congestive Heart Failure With Preserved Left Ventricular Ejection Fraction |
Terminated |
NCT00840463 |
Phase 4 |
Ambrisentan |
| 23 |
Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction |
Unknown status |
NCT01583881 |
Phase 2, Phase 3 |
|
| 24 |
Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial] |
Unknown status |
NCT01599117 |
Phase 3 |
Placebo;Udenafil (Zydena) |
| 25 |
Exercise Intolerance in Elderly Diastolic Heart Failure |
Completed |
NCT00123955 |
Phase 3 |
Spironolactone;Placebo |
| 26 |
Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure |
Completed |
NCT01411735 |
Phase 3 |
Enalapril;placebo |
| 27 |
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) |
Completed |
NCT00763867 |
Phase 3 |
Placebo;Sildenafil |
| 28 |
Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension |
Completed |
NCT01726049 |
Phase 3 |
Sildenafil;Placebo |
| 29 |
Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study |
Completed |
NCT01156636 |
Phase 2, Phase 3 |
Sildenafil;Placebo |
| 30 |
Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) |
Completed |
NCT00094302 |
Phase 3 |
Spironolactone;Placebo |
| 31 |
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction |
Completed |
NCT01920711 |
Phase 3 |
LCZ696;Valsartan |
| 32 |
Aldosterone-blockade Randomized Controlled Trial In CHF - Diastolic |
Completed |
NCT00523757 |
Phase 3 |
Spironolactone;Placebo |
| 33 |
Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension |
Completed |
NCT00820352 |
Phase 3 |
bosentan;placebo |
| 34 |
Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months |
Completed |
NCT00775840 |
Phase 3 |
Candesartan;Placebo |
| 35 |
MB001-067 A PROSPECTIVE, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, RANDOMIZED TRIAL OF EXTENDED RELEASE EXENATIDE VERSUS PLACEBO (COHORT A) AND A PROSPECTIVE, SINGLE GROUP, OPEN-LABEL, BLINDED OUTCOME TRIAL OF EXTENDED RELEASE EXENATIDE (COHORT B) IN DIABETIC PATIENTS WITH TYPE 4 CARDIORENAL SYNDROME (EXTEND-CRS TRIAL) AMENDMENT 3 |
Recruiting |
NCT02251431 |
Phase 3 |
BYDUREON;Placebo |
| 36 |
Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) (OPTIMIZE-HFPEF) |
Recruiting |
NCT02425371 |
Phase 3 |
|
| 37 |
A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer |
Terminated |
NCT01708798 |
Phase 2, Phase 3 |
Eplerenone;Placebo |
| 38 |
A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study |
Completed |
NCT00043836 |
Phase 2 |
ALT-711 |
| 39 |
A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure. |
Completed |
NCT00309868 |
Phase 1, Phase 2 |
neseritide |
| 40 |
A Phase 2 Randomised, Double-Blind, Placebo-Controlled Exploratory Efficacy Study Of Sitaxsentan Sodium To Improve Impaired Exercise Tolerance In Subjects With Diastolic Heart Failure |
Completed |
NCT00303498 |
Phase 2 |
Sitaxsentan sodium;Placebo |
| 41 |
Evaluation of Efficacy and Safety of Metoprolol XR in Patients Having Heart Failure With Normal Ejection Fraction: A Randomised, Double Blind,Placebo Controlled Trial |
Completed |
NCT03882710 |
Phase 2 |
Metoprolol XR |
| 42 |
A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction |
Completed |
NCT01163734 |
Phase 2 |
Ranolazine |
| 43 |
Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF) |
Completed |
NCT00839228 |
Phase 2 |
Perhexiline;Placebo |
| 44 |
To Define in Normal Controls, Human Preclinical Systolic Dysfunction (PSD) and Preclinical Diastolic Dysfunction (PDD) the Actions of Acute Subcutaneous Nesiritide (BNP) on the Cardiorenal and Humoral Function and the Integrated Response to Acute Sodium Loading |
Completed |
NCT00387621 |
Phase 1, Phase 2 |
Nesiritide;Placebo;Saline |
| 45 |
Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function |
Completed |
NCT01182805 |
Phase 1, Phase 2 |
|
| 46 |
Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF |
Completed |
NCT02256345 |
Phase 2 |
KNO3;KCl |
| 47 |
A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension |
Completed |
NCT01431313 |
Phase 2 |
Inhaled Nitrite |
| 48 |
Interleukin-1 Blockade in Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Placebo-controlled Double Blinded Study (D-HART2) |
Completed |
NCT02173548 |
Phase 2 |
Anakinra;Placebo |
| 49 |
Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose |
Recruiting |
NCT03133793 |
Phase 2 |
CoQ10;D-Ribose Oral Powder |
| 50 |
Regress-HFPEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs |
Recruiting |
NCT02941705 |
Phase 2 |
|
|
